Golidocitinib vs placebo for T-cell lymphoma maintenance
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if taking golidocitinib pills after first treatment helps keep peripheral T-cell lymphoma from coming back. You'll either get the study drug or a placebo (no active drug), and your doctor will watch how you do.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of T-cell lymphoma (PTCL, ALK+ ALCL, AITL, or TFH-type) that shrunk after your first chemotherapy (like CHOP or similar).
- You are either over 65 and cannot have a stem cell transplant, or you are 65 or younger and choose not to have one.
- You start this study within 3 months of finishing your last chemo.
- Your blood counts and organ function (kidney, liver, heart) are good enough, as checked by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a daily pill called golidocitinib can keep your PTCL from coming back after you've had a good response to your first chemotherapy. The study compares the drug to a placebo (a pill with no active medicine) to see if it helps prevent relapse.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This study looks at how well a medicine called golidocitinib, given alone or with other treatments, works for people with peripheral T-cell lymphoma (a type of blood cancer). It is a real-world study, meaning it follows patients who are already receiving this treatment in regular medical care.
This study tests a new pill called golidocitinib for people newly diagnosed with certain types of peripheral T-cell lymphoma who have not been treated before. The goal is to see if it is safe and effective in shrinking or controlling the lymphoma.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
Hear when a new Maintenance Treatment of Peripheral T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.